In Feb, we added 97 citations in DIDB, including 51 in vitro (with 25 articles published in Feb 2026) and 46 in vivo articles (with 39 articles published in Feb 2026).
5 NDAs and 4 BLAs approved by the FDA in 2025, including aficamten (MYQORZO), elinzanetant (LYNKUET), linvoseltamab (LYNOZYFIC), narsoplimab (YARTEMLEA), pembrolizumab and berahyaluronidase alfa (KYTRUDA QLEX), penpulimab (PENPULIMAB), sevabertinib (HYRNUO), tradipitant (NEREUS), and ziftomenib (KOMZIFTI), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.